{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:03:54Z","timestamp":1772247834993,"version":"3.50.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,31]],"date-time":"2013-12-31T00:00:00Z","timestamp":1388448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0084059","type":"journal-article","created":{"date-parts":[[2013,12,31]],"date-time":"2013-12-31T22:09:19Z","timestamp":1388527759000},"page":"e84059","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease"],"prefix":"10.1371","volume":"8","author":[{"given":"Pei-Hsuan","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Hau","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Keung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Min","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,12,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer&apos;s disease: a disorder of cortical cholinergic innervation","volume":"219","author":"JT Coyle","year":"1983","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF00964952","article-title":"Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer&apos;s dementia","volume":"14","author":"ED London","year":"1989","journal-title":"Neurochem Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1212\/WNL.51.1_Suppl_1.S30","article-title":"Development of acetylcholinesterase inhibitors in the therapy of Alzheimer&apos;s disease","volume":"51","author":"P Taylor","year":"1998","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1479-7364-4-2-91","article-title":"Cholinesterase inhibitors in Alzheimer&apos;s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story","volume":"4","author":"B Lam","year":"2009","journal-title":"Hum Genomics"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00008571-200304000-00008","article-title":"Regulation of attention and response to therapy in dementia by butyrylcholinesterase","volume":"13","author":"KK O'Brien","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","article-title":"Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer&apos;s disease","volume":"16","author":"R Blesa","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/tpj.2010.61","article-title":"Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer&apos;s disease","volume":"11","author":"CE Patterson","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajmg.b.30846","article-title":"Variability of <italic>AChE<\/italic>, <italic>BChE<\/italic>, and <italic>ChAT<\/italic> genes in the late-onset form of Alzheimer&apos;s disease and relationships with response to treatment with Donepezil and Rivastigmine","volume":"150B","author":"R Scacchi","year":"2009","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.fpc.0000189799.88596.04","article-title":"A single nucleotide polymorphism in <italic>CHAT<\/italic> influences response to acetylcholinesterase inhibitors in Alzheimer&apos;s disease","volume":"16","author":"D Harold","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-011-1064-x","article-title":"<italic>BCHE<\/italic> and <italic>CYP2D6<\/italic> genetic variation in Alzheimer&apos;s disease patients treated with cholinesterase inhibitors","volume":"67","author":"C Chianella","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer&apos;s disease","volume":"52","author":"M Noetzli","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/WNL.0b013e3181b6bbe3","article-title":"Effect of a <italic>CYP2D6<\/italic> polymorphism on the efficacy of donepezil in patients with Alzheimer disease","volume":"73","author":"A Pilotto","year":"2009","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00406-007-1006-x","article-title":"Pharmacogenomics and therapeutic prospects in dementia","volume":"258","author":"R Cacabelos","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/dmd.30.5.553","article-title":"The metabolism and excretion of galantamine in rats, dogs, and humans","volume":"30","author":"GS Mannens","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"ref15","volume":"34","unstructured":"Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, <etal>et al<\/etal>.. (2013) Pharmacogenomics in Alzheimer&apos;s disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiol Aging <volume>34<\/volume> : 1711 e1717\u20131713."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/aje\/kwn353","article-title":"Gene-environment interaction in genome-wide association studies","volume":"169","author":"CE Murcray","year":"2009","journal-title":"Am J Epidemiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jmg.2007.052704","article-title":"Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer&apos;s disease","volume":"45","author":"R Carson","year":"2008","journal-title":"J Med Genet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.neurobiolaging.2007.11.003","article-title":"<italic>APOE<\/italic>, <italic>ACT<\/italic> and <italic>CHRNA7<\/italic> genes in the conversion from amnestic mild cognitive impairment to Alzheimer&apos;s disease","volume":"30","author":"A Barabash","year":"2009","journal-title":"Neurobiol Aging"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1523\/JNEUROSCI.18-20-08228.1998","article-title":"Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons","volume":"18","author":"CJ Frazier","year":"1998","journal-title":"J Neurosci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00002093-200108001-00004","article-title":"Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease","volume":"15","author":"EX Albuquerque","year":"2001","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/sj.bjp.0706221","article-title":"Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity","volume":"145","author":"L Texido","year":"2005","journal-title":"Br J Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0083-6729(10)82014-X","article-title":"Sex steroids and acetylcholine release in the hippocampus","volume":"82","author":"D Mitsushima","year":"2010","journal-title":"Vitam Horm"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0165-0173(99)00011-9","article-title":"Functional sex differences (&apos;sexual diergism&apos;) of central nervous system cholinergic systems, vasopressin, and hypothalamic-pituitary-adrenal axis activity in mammals: a selective review","volume":"30","author":"ME Rhodes","year":"1999","journal-title":"Brain Res Brain Res Rev"},{"key":"ref24","volume":"61","unstructured":"Koylu E, Demirgoren S, London ED, Pogun S (1997) Sex difference in up-regulation of nicotinic acetylcholine receptors in rat brain. Life Sci <volume>61<\/volume> : PL 185\u2013190."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0197-4580(86)90042-4","article-title":"Age and sex-dependent decreases in ChAT in basal forebrain nuclei","volume":"7","author":"VN Luine","year":"1986","journal-title":"Neurobiol Aging"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e20573","DOI":"10.1371\/journal.pone.0020573","article-title":"Genetic polymorphisms of a novel vascular susceptibility gene, <italic>Ninjurin2<\/italic> (<italic>NINJ2<\/italic>), are associated with a decreased risk of Alzheimer&apos;s disease","volume":"6","author":"KP Lin","year":"2011","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer&apos;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&apos;s Disease","volume":"34","author":"G McKhann","year":"1984","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d","volume":"12","author":"MF Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0895-4356(88)90034-0","article-title":"A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey","volume":"41","author":"R Katzman","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"ref30","first-page":"227","article-title":"US Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting","volume":"1989","journal-title":"Rockville (MD): Department of Health and Human Services, Public Health Service"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1212\/WNL.48.6.1511","article-title":"The Alzheimer&apos;s Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer&apos;s disease trials","volume":"48","author":"PM Doraiswamy","year":"1997","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1126\/science.1069424","article-title":"The structure of haplotype blocks in the human genome","volume":"296","author":"SB Gabriel","year":"2002","journal-title":"Science"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1158\/0008-5472.CAN-05-2078","article-title":"Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer","volume":"65","author":"YC Chen","year":"2005","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000073202","article-title":"Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals","volume":"55","author":"DO Stram","year":"2003","journal-title":"Hum Hered"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1212\/WNL.46.5.1484-a","article-title":"A simple and efficient method for apolipoprotein E genotype determination","volume":"46","author":"J Chapman","year":"1996","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.archger.2008.07.006","article-title":"Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer&apos;s disease: a 21-month follow-up \u201creal world\u201d study","volume":"49","author":"M Calabria","year":"2009","journal-title":"Arch Gerontol Geriatr"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","article-title":"An efficacy and safety analysis of Exelon in Alzheimer&apos;s disease patients with concurrent vascular risk factors","volume":"7","author":"V Kumar","year":"2000","journal-title":"Eur J Neurol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.1073\/pnas.92.26.12260","article-title":"Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease","volume":"92","author":"J Poirier","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate \u2013 a Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Y Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society Series B-Methodological"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/sim.4780141908","article-title":"Exact logistic regression: theory and examples","volume":"14","author":"CR Mehta","year":"1995","journal-title":"Stat Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature09000","article-title":"Deciphering the splicing code","volume":"465","author":"Y Barash","year":"2010","journal-title":"Nature"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bej.2009.12.021","article-title":"From SNPs to functional polymorphism: The insight into biotechnology applications","volume":"49","author":"PY Liao","year":"2010","journal-title":"Biochemical Engineering Journal"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2006.04.007","article-title":"Acetylcholinesterase inhibitors used in treatment of Alzheimer&apos;s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade","volume":"51","author":"Y Takada-Takatori","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12031-009-9236-1","article-title":"Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection","volume":"40","author":"A Akaike","year":"2010","journal-title":"J Mol Neurosci"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1385\/JMN:30:1:137","article-title":"Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters","volume":"30","author":"S Wonnacott","year":"2006","journal-title":"J Mol Neurosci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2005.10.028","article-title":"Up- regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons","volume":"527","author":"T Kume","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2004.11.042","article-title":"Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits","volume":"1033","author":"H Geerts","year":"2005","journal-title":"Brain Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0084059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:42:28Z","timestamp":1716378148000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0084059"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Yamanishi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,31]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0084059","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,31]]}}}